Predict your next investment

MAX BioPharma company logo
HEALTHCARE | Drug Development
maxbiopharma.com

See what CB Insights has to offer

Stage

Grant - II | Alive

About MAX BioPharma

MAX BioPharma is a start up biopharmaceutical company engaged in discovery and development of small molecules to target human disorders including non-healing bone fractures, osteoporosis, and cancer. The company is a provider in the fields of "lipidomics" and "oxysterol therapeutics" by leveraging a growing portfolio of IP that will lead to treatments for numerous indications. MAX BioPharma's first success based on small molecule lipids has contributed to the discovery of osteogenic oxysterol compounds that target multipotent mesenchymal cells, including mesenchymal stem cells, to induce the formation bone forming osteoblasts and bone in vitro and in vivo. The company is developing this technology into the next generation of therapeutic agents for stimulation of bone formation locally and systemically in indications such as spinal fusion, non-union fractures, and osteoporosis. MAX BioPharma is also pursuing the development of small molecule oxysterols that function as Hedgehog pathway antagonists in tumor microenvironment and will be more effective than currently known Hedgehog pathway antagonists in treating a variety of Hedgehog pathway-related cancers, including pancreatic cancer and multiple myeloma.

MAX BioPharma Headquarter Location

Los Angeles, California,

United States

310-283-2596

Latest MAX BioPharma News

10:49 ET $ 328.39 Million growth expected in Global Hedgehog Pathway Inhibitors Market 2021-2025 | Technavio

Jun 21, 2021

| Technavio Hedgehog pathway inhibitors market to witness 11.55% YOY growth in 2021 F. Hoffmann-La Roche Ltd., Inhibitor Therapeutics Inc., and MAX BioPharma Inc. will emerge as top hedgehog pathway inhibitors market vendors News provided by Share this article NEW YORK, June 21, 2021 /PRNewswire/ -- The hedgehog pathway inhibitors market is expected to grow by USD 328.39 million during 2021-2025, according to Technavio. The report offers a detailed analysis of the impact of the COVID-19 pandemic on the hedgehog pathway inhibitors market in optimistic, probable, and pessimistic forecast scenarios. Technavio has announced its latest market research report titled Hedgehog Pathway Inhibitors Market by Indication and Geography - Forecast and Analysis 2021-2025 The hedgehog pathway inhibitors market will witness a neutral impact during the forecast period owing to the widespread growth of the COVID-19 pandemic. As per Technavio's pandemic-focused market research, market growth is likely to increase in 2021 as compared to 2020. With the continuing spread of the coronavirus pandemic, organizations across the globe are gradually flattening their recessionary curve by leveraging technology. Many businesses will go through response, recovery, and renewal phases. Building business resilience and enabling agility will aid organizations to move forward in their journey out of the COVID-19 crisis towards the Next Normal. Key Considerations for Market Forecast: Impact of lockdowns, supply chain disruptions, demand destruction, and change in customer behavior Optimistic, probable, and pessimistic scenarios for all markets as the impact of pandemic unfolds Pre- as well as post-COVID-19 market estimates Quarterly impact analysis and updates on market estimates The hedgehog pathway inhibitors market is driven by the high-risk factors for BCC and AML. In addition, the increasing awareness about BCC and AML are expected to trigger the hedgehog pathway inhibitors market toward witnessing a CAGR of almost 13% during the forecast period. Gain more insights about the global trends impacting the future of the hedgehog pathway inhibitors market, Request Free Sample @  https://www.technavio.com/talk-to-us?report=IRTNTR70615 Major Five Hedgehog Pathway Inhibitors Market Participants: F. Hoffmann-La Roche Ltd.: The company offers Erivedge which is used for the treatment of adults with metastatic BCC or with locally advanced BCC. The recommended dose is one daily oral dose of 150 mg. Inhibitor Therapeutics Inc.: The company offers SUBA-Itraconazole which is a patented formulation of itraconazole developed by Mayne Pharma, which is designed to improve the bioavailability of orally administered drugs that are poorly soluble. MAX BioPharma Inc.: The company offers Oxysterols that are oxidized derivatives of cholesterol that can be activators or inhibitors of specific cellular signaling pathways, including Hedgehog and TGF pathways. Mayne Pharma Group Ltd.: The company offers TOLSURA (SUBA-itraconazole) Capsules which is an azole antifungal indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised adult patients. PellePharm Inc.: Patidegib is the key product of the company. It is under development for the treatment of BCC. Hedgehog Pathway Inhibitors Market 2021-2025: Segmentation Hedgehog pathway inhibitors market is segmented as below: Geography About Us Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing MAX BioPharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

MAX BioPharma is included in 1 Expert Collection, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

MAX BioPharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

MAX BioPharma Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.